Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:54:14 2024-04-18 pm EDT			5-day change	1st Jan Change
0.94 ^USD	-2.34%		-4.08%	-21.67%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Mar. 13	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	CI

ELOXX PHARMACEUTICALS, INC. : Other Events (form 8-K)

June 17, 2020 at 04:48 pm EDT

Item 8.01. Other Events.

On June 17, 2020, Eloxx Pharmaceuticals, Inc. (the "Company") issued a press release indicating that clinical trials have been resumed in Israel and Europe after being temporarily paused in response to the COVID-19 pandemic. A copy of the Company's press release is being furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Latest news about Eloxx Pharmaceuticals, Inc.

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	Mar. 13	CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13	MT
Eloxx Pharmaceuticals, Inc. Enters into the Fifth Amendment to the Loan and Security Agreement	Jan. 09	CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board	Dec. 28	CI
Eloxx Pharmaceuticals, Inc. and Zikani Therapeutics, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement	Dec. 15	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Oppenheimer Adjusts Eloxx Pharmaceuticals Price Target to $30 From $60, Maintains Outperform Rating	Nov. 02	MT
Eloxx Pharmaceuticals, Inc.(NasdaqCM:ELOX) dropped from S&P TMI Index	23-10-18	CI
Eloxx Pharmaceuticals, Inc.(OTCPK:ELOX) dropped from NASDAQ Composite Index	23-10-13	CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development	23-09-15	CI
Oppenheimer Raises Eloxx Pharmaceuticals Price Target to $60 From $55, Maintains Outperform Rating	23-09-14	MT
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013	23-09-07	CI
Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	23-08-14	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Top Premarket Gainers	23-07-12	MT
Top Midday Gainers	23-07-11	MT
Oppenheimer Adjusts Eloxx Pharmaceuticals' Price Target to $55 From $50, Keeps Outperform Rating	23-07-11	MT
Transcript : Eloxx Pharmaceuticals, Inc. - Shareholder/Analyst Call	23-06-27
Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients	23-06-14	CI
Top Premarket Decliners	23-05-16	MT
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013	23-05-02	CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Eloxx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI

Chart Eloxx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.94 USD

Average target price

30 USD

Spread / Average Target

+3,091.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELOXX PHARMACEUTICALS, INC.	-21.67%	3.1M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.98%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.56%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs